Skip to Content
You are currently on the new version of our website. Access the old version .
CancersCancers
  • Review
  • Open Access

24 April 2021

21 Pages

The PARP Enzyme Family and the Hallmarks of Cancer Part 2: Hallmarks Related to Cancer Host Interactions

and
1
Department of Medical Chemistry, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary
2
MTA-DE Cell Biology and Signaling Research Group, 4032 Debrecen, Hungary
*
Authors to whom correspondence should be addressed.
This article belongs to the Special Issue PARPs in Cancer

Simple Summary

Members of the poly (ADP-ribose)-polymerase (PARP) enzyme family regulate a broad range of cellular functions related to carcinogenesis, tumor growth, cell death, replicative immortality, and metabolism. In the companion paper (part 1) to this review, we covered how the 17 members of the PARP1 family affect these intrinsic cancer cell hallmarks. Here, we explore the PARP association of cancer hallmarks that derive from tissue-level reorganization in tumors and interactions of cancer cells with the tumor stroma. Thus, the focus of this review will be on the roles played by PARPs in tumor invasion, metastasis, anticancer immune responses, and tumor-associated inflammation. We present mechanisms that may enhance or weaken the therapeutic efficiency of PARP inhibitors and discuss the potential targeting of non-DNA dependent PARPs.

Abstract

Poly (ADP-ribose) polymerases (PARPs) modify target proteins with a single ADP-ribose unit or with a poly (ADP-ribose) (PAR) polymer. PARP inhibitors (PARPis) recently became clinically available for the treatment of BRCA1/2 deficient tumors via the synthetic lethality paradigm. This personalized treatment primarily targets DNA damage-responsive PARPs (PARP1–3). However, the biological roles of PARP family member enzymes are broad; therefore, the effects of PARPis should be viewed in a much wider context, which includes complex effects on all known hallmarks of cancer. In the companion paper (part 1) to this review, we presented the fundamental roles of PARPs in intrinsic cancer cell hallmarks, such as uncontrolled proliferation, evasion of growth suppressors, cell death resistance, genome instability, replicative immortality, and reprogrammed metabolism. In the second part of this review, we present evidence linking PARPs to cancer-associated inflammation, anti-cancer immune response, invasion, and metastasis. A comprehensive overview of the roles of PARPs can facilitate the identification of novel cancer treatment opportunities and barriers limiting the efficacy of PARPi compounds.

1. Introduction

In two seminal papers, Hanahan and Weinberg proposed a set of quintessential traits that define cancer [1,2]. Six of these cancer hallmarks describe altered behaviors of transformed cells compared to their normal counterparts. According to these six hallmarks, cancer cells are characterized by genomic instability, sustained proliferative signaling, evasion of growth-suppressive signals, replicative immortality, altered metabolism, and resistance to cell death. In addition to these intrinsic cancer cell traits, four additional hallmarks/enabling characteristics define interactions between cancer tissue and the host organism [1]. This second set of hallmarks emphasize our view that cancer is a systemic disease, and cannot be adequately understood by scrutinizing only cancer cells. In other words, a tumor is closer to a complex organ than a lump of hyperproliferative cells. This second set of hallmarks arises from the derangement of signaling pathways arising from both the transformed cell and the homo- and heterotypic interactions between cancer cells, immune cells, and parenchymal or stromal cells. In the past decade, the interplay between the tumor and its microenvironment has become the prevailing direction of cancer research and the area from which the newest therapeutic modalities are emerging. The first regulatory body approval of a cancer immunotherapy in 2008; the approval of the first immune checkpoint inhibitor antibody by the FDA in 2011, followed by six others to date; the first approved chimeric antigen receptor (CAR) T-cell treatment in 2017; and hundreds of ongoing clinical trials all highlight promising new avenues for cancer treatment involving manipulation of the immune system’s interaction with transformed cells.
All hallmarks of cancer are closely intertwined with poly (ADP-ribose) polymerase (PARP)-mediated activities, and hallmarks related to cancer–host crosstalk are no exception. The PARP enzyme family, also known as ARTD (diphtheria toxin-like ADP-ribosyltransferase) enzymes [3], modify proteins with a single ADP-ribose residue (mono-ADP-ribosylation, MARylation) or poly(ADP-ribose) polymers (poly-ADP-ribosylation, PARylation) [4]. These enzymes are implicated in the regulation of the most fundamental cell functions, including genome maintenance, DNA repair, cell death, cell proliferation, and transcription [5,6,7,8,9,10,11]. In the first part of these twin reviews, we presented the fundamental roles of PARPs in intrinsic cancer cell hallmarks [12]. In the second part, we present evidence linking PARPs to cancer-associated inflammation, anti-cancer immune response, invasion of surrounding healthy tissues, and metastasis to remote organs.

3. Conclusions

Our current understanding of the complex role of PARylation enzymes in cancer cell non-intrinsic hallmarks is very limited. The most detailed picture we have is about the proinflammatory role of PARP-1. However, there are a number of unknowns, including (a) whether and how the proinflammatory effects of PARP1 impact cancer-associated inflammation; (b) whether inhibition of cancer-associated inflammation by PARPis provides therapeutic benefits, and (c) how spatiotemporal factors and tumor-specific differences modulate such potential anticancer effects. PARPs other than PARP-1 also play widespread roles in inflammation. However, none of these effects have been investigated in the context of cancer-associated inflammation. Specific targeting tools are clearly needed to address burning questions in this exciting field. One of the most promising lines of investigation is focused on the crossroads of immune checkpoint regulation and synthetic lethality by PARPi. However, the dependence of targeted anticancer cell therapy efficiency on PARPs is unknown. Based on the information discussed in this paper, the possibility that PARP/PARylation-targeted therapies may also help alleviate the most feared cancer hallmark, invasion and metastasis, cannot be excluded.

Author Contributions

Both authors contributed equally to the manuscript. M.A.D. and L.V. reviewed and analyzed literature, formed concepts, and wrote the manuscript. All authors have read and agreed to the published version of the manuscript

Funding

L.V. received funding from the National Research, Development, and Innovation Office grants GINOP-2.3.2-15-2016-00020 TUMORDNS”, GINOP-2.3.2-15-2016-00048-STAYALIVE, and OTKA K132193.

Institutional Review Board Statement

Not applicable.

Data Availability Statement

No new data were created or analyzed in this study. Data sharing is not applicable to this article.

Acknowledgments

The authors are grateful to Karen Uray for the careful English language editing of the manuscript. The figures were created with BioRender.com.

Conflicts of Interest

The authors declare that they have no competing interests.

References

  1. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70. [Google Scholar] [CrossRef] [Scilit]
  2. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  3. Hottiger, M.O.; Hassa, P.O.; Lüscher, B.; Schüler, H.; Koch-Nolte, F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem. Sci. 2010, 35, 208–219. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  4. Hassa, P.O.; Hottiger, M.O. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci. 2008, 13, 3046–3082. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  5. Burkle, A.; Virag, L. Poly(ADP-ribose): PARadigms and PARadoxes. Mol. Aspects Med. 2013, 34, 1046–1065. [Google Scholar] [CrossRef] [Scilit]
  6. Hegedus, C.; Virag, L. Inputs and outputs of poly(ADP-ribosyl)ation: Relevance to oxidative stress. Redox Biol. 2014, 2, 978–982. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  7. Robinson, N.; Ganesan, R.; Hegedus, C.; Kovacs, K.; Kufer, T.A.; Virag, L. Programmed necrotic cell death of macrophages: Focus on pyroptosis, necroptosis, and parthanatos. Redox Biol. 2019, 26, 101239. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  8. Virag, L. The expanding universe of poly(ADP-ribosyl)ation. Cell. Mol. Life Sci. 2005, 62, 719–720. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  9. Virag, L. 50 Years of poly(ADP-ribosyl)ation. Mol. Aspects Med. 2013, 34, 1043–1045. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  10. Virag, L.; Robaszkiewicz, A.; Rodriguez-Vargas, J.M.; Oliver, F.J. Poly(ADP-ribose) signaling in cell death. Mol. Aspects Med. 2013, 34, 1153–1167. [Google Scholar] [CrossRef] [Scilit]
  11. Virag, L.; Szabo, C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 2002, 54, 375–429. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  12. Demény, M.A.; Virág, L. The PARP enzyme family and the hallmarks of cancer. Part 1. Cell intrinsic hallmarks. Cancers (Basel) 2021, 13, 2042. [Google Scholar] [CrossRef] [Scilit]
  13. Jayson, G.C.; Kerbel, R.; Ellis, L.M.; Harris, A.L. Antiangiogenic therapy in oncology: Current status and future directions. Lancet 2016, 388, 518–529. [Google Scholar] [CrossRef] [Scilit]
  14. Nishida, N.; Yano, H.; Nishida, T.; Kamura, T.; Kojiro, M. Angiogenesis in cancer. Vasc. Health Risk Manag. 2006, 2, 213–219. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  15. Liekens, S.; Schols, D.; Hatse, S. CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr. Pharm. Des. 2010, 16, 3903–3920. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  16. Chu, S.H.; Feng, D.F.; Ma, Y.B.; Zhu, Z.A.; Zhang, H.; Qiu, J.H. Stabilization of hepatocyte growth factor mRNA by hypoxia-inducible factor 1. Mol. Biol. Rep. 2009, 36, 1967–1975. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  17. Yu, F.; Lin, Y.; Zhan, T.; Chen, L.; Guo, S. HGF expression induced by HIF-1alpha promote the proliferation and tube formation of endothelial progenitor cells. Cell Biol. Int. 2015, 39, 310–317. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  18. Rey, S.; Semenza, G.L. Hypoxia-inducible factor-1-dependent mechanisms of vascularization and vascular remodelling. Cardiovasc. Res. 2010, 86, 236–242. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  19. Tentori, L.; Lacal, P.M.; Muzi, A.; Dorio, A.S.; Leonetti, C.; Scarsella, M.; Ruffini, F.; Xu, W.; Min, W.; Stoppacciaro, A.; et al. Poly(ADP-ribose) polymerase (PARP) inhibition or PARP-1 gene deletion reduces angiogenesis. Eur. J. Cancer 2007, 43, 2124–2133. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  20. Tentori, L.; Muzi, A.; Dorio, A.S.; Bultrini, S.; Mazzon, E.; Lacal, P.M.; Shah, G.M.; Zhang, J.; Navarra, P.; Nocentini, G.; et al. Stable depletion of poly (ADP-ribose) polymerase-1 reduces in vivo melanoma growth and increases chemosensitivity. Eur. J. Cancer 2008, 44, 1302–1314. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  21. Martínez-Romero, R.; Cañuelo, A.; Martínez-Lara, E.; Javier Oliver, F.; Cárdenas, S.; Siles, E. Poly(ADP-ribose) polymerase-1 modulation of in vivo response of brain hypoxia-inducible factor-1 to hypoxia/reoxygenation is mediated by nitric oxide and factor inhibiting HIF. J. Neurochem. 2009, 111, 150–159. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  22. Martínez-Romero, R.; Martínez-Lara, E.; Aguilar-Quesada, R.; Peralta, A.; Oliver, F.J.; Siles, E. PARP-1 modulates deferoxamine-induced HIF-1alpha accumulation through the regulation of nitric oxide and oxidative stress. J. Cell. Biochem. 2008, 104, 2248–2260. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  23. Elser, M.; Borsig, L.; Hassa, P.O.; Erener, S.; Messner, S.; Valovka, T.; Keller, S.; Gassmann, M.; Hottiger, M.O. Poly(ADP-ribose) polymerase 1 promotes tumor cell survival by coactivating hypoxia-inducible factor-1-dependent gene expression. Mol. Cancer Res. 2008, 6, 282–290. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  24. Gonzalez-Flores, A.; Aguilar-Quesada, R.; Siles, E.; Pozo, S.; Rodríguez-Lara, M.I.; López-Jiménez, L.; López-Rodríguez, M.; Peralta-Leal, A.; Villar, D.; Martín-Oliva, D.; et al. Interaction between PARP-1 and HIF-2α in the hypoxic response. Oncogene 2014, 33, 891–898. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  25. Marti, J.M.; Garcia-Diaz, A.; Delgado-Bellido, D.; O’Valle, F.; Gonzalez-Flores, A.; Carlevaris, O.; Rodriguez-Vargas, J.M.; Ame, J.C.; Dantzer, F.; King, G.L.; et al. Selective modulation by PARP-1 of HIF-1alpha-recruitment to chromatin during hypoxia is required for tumor adaptation to hypoxic conditions. Redox Biol. 2021, 41, 101885. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  26. Martin-Oliva, D.; Aguilar-Quesada, R.; O’Valle, F.; Muñoz-Gámez, J.A.; Martínez-Romero, R.; García Del Moral, R.; Ruiz de Almodóvar, J.M.; Villuendas, R.; Piris, M.A.; Oliver, F.J. Inhibition of poly(ADP-ribose) polymerase modulates tumor-related gene expression, including hypoxia-inducible factor-1 activation, during skin carcinogenesis. Cancer Res. 2006, 66, 5744–5756. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  27. Quiles-Perez, R.; Munoz-Gamez, J.A.; Ruiz-Extremera, A.; O’Valle, F.; Sanjuan-Nunez, L.; Martin-Alvarez, A.B.; Martin-Oliva, D.; Caballero, T.; Munoz de Rueda, P.; Leon, J.; et al. Inhibition of poly adenosine diphosphate-ribose polymerase decreases hepatocellular carcinoma growth by modulation of tumor-related gene expression. Hepatology 2010, 51, 255–266. [Google Scholar] [CrossRef] [Scilit]
  28. Martín-Oliva, D.; O’Valle, F.; Muñoz-Gámez, J.A.; Valenzuela, M.T.; Nuñez, M.I.; Aguilar, M.; Ruiz de Almodóvar, J.M.; Garcia del Moral, R.; Oliver, F.J. Crosstalk between PARP-1 and NF-kappaB modulates the promotion of skin neoplasia. Oncogene 2004, 23, 5275–5283. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  29. Rajesh, M.; Mukhopadhyay, P.; Godlewski, G.; Bátkai, S.; Haskó, G.; Liaudet, L.; Pacher, P. Poly(ADP-ribose)polymerase inhibition decreases angiogenesis. Biochem. Biophys. Res. Commun. 2006, 350, 1056–1062. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  30. Rajesh, M.; Mukhopadhyay, P.; Bátkai, S.; Godlewski, G.; Haskó, G.; Liaudet, L.; Pacher, P. Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis. Biochem. Biophys. Res. Commun. 2006, 350, 352–357. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  31. Jia, J.; Ye, T.; Cui, P.; Hua, Q.; Zeng, H.; Zhao, D. AP-1 transcription factor mediates VEGF-induced endothelial cell migration and proliferation. Microvasc. Res. 2016, 105, 103–108. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  32. Zingarelli, B.; Hake, P.W.; O’Connor, M.; Denenberg, A.; Wong, H.R.; Kong, S.; Aronow, B.J. Differential regulation of activator protein-1 and heat shock factor-1 in myocardial ischemia and reperfusion injury: Role of poly(ADP-ribose) polymerase-1. Am. J. Physiol. Heart Circ. Physiol. 2004, 286, H1408–H1415. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  33. Andreone, T.L.; O’Connor, M.; Denenberg, A.; Hake, P.W.; Zingarelli, B. Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts. J. Immunol. 2003, 170, 2113–2120. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  34. Wagner, S.; Hussain, M.Z.; Beckert, S.; Ghani, Q.P.; Weinreich, J.; Hunt, T.K.; Becker, H.D.; Königsrainer, A. Lactate down-regulates cellular poly(ADP-ribose) formation in cultured human skin fibroblasts. Eur J. Clin. Investig. 2007, 37, 134–139. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  35. Kumar, V.B.; Viji, R.I.; Kiran, M.S.; Sudhakaran, P.R. Endothelial cell response to lactate: Implication of PAR modification of VEGF. J. Cell. Physiol. 2007, 211, 477–485. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  36. Tolić, A.; Grdović, N.; Dinić, S.; Rajić, J.; Đorđević, M.; Sinadinović, M.; Arambašić Jovanović, J.; Mihailović, M.; Poznanović, G.; Uskoković, A.; et al. Absence of PARP-1 affects Cxcl12 expression by increasing DNA demethylation. J. Cell. Mol. Med. 2019, 23, 2610–2618. [Google Scholar] [CrossRef] [Scilit]
  37. Kim, T.H.; Hur, E.G.; Kang, S.J.; Kim, J.A.; Thapa, D.; Lee, Y.M.; Ku, S.K.; Jung, Y.; Kwak, M.K. NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Res. 2011, 71, 2260–2275. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  38. Wu, T.; Wang, X.J.; Tian, W.; Jaramillo, M.C.; Lau, A.; Zhang, D.D. Poly(ADP-ribose) polymerase-1 modulates Nrf2-dependent transcription. Free Radic. Biol. Med. 2014, 67, 69–80. [Google Scholar] [CrossRef] [Scilit]
  39. Baudino, T.A.; McKay, C.; Pendeville-Samain, H.; Nilsson, J.A.; Maclean, K.H.; White, E.L.; Davis, A.C.; Ihle, J.N.; Cleveland, J.L. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 2002, 16, 2530–2543. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  40. Mostocotto, C.; Carbone, M.; Battistelli, C.; Ciotti, A.; Amati, P.; Maione, R. Poly(ADP-ribosyl)ation is required to modulate chromatin changes at c-MYC promoter during emergence from quiescence. PLoS ONE 2014, 9, e102575. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  41. Zhang, Y.; Liu, S.; Mickanin, C.; Feng, Y.; Charlat, O.; Michaud, G.A.; Schirle, M.; Shi, X.; Hild, M.; Bauer, A.; et al. RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling. Nat. Cell Biol. 2011, 13, 623–629. [Google Scholar] [CrossRef] [Scilit]
  42. Feijs, K.L.; Kleine, H.; Braczynski, A.; Forst, A.H.; Herzog, N.; Verheugd, P.; Linzen, U.; Kremmer, E.; Lüscher, B. ARTD10 substrate identification on protein microarrays: Regulation of GSK3β by mono-ADP-ribosylation. Cell Commun. Signal 2013, 11, 5. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  43. Rodríguez, M.I.; Majuelos-Melguizo, J.; Martí Martín-Consuegra, J.M.; Ruiz de Almodóvar, M.; López-Rivas, A.; Javier Oliver, F. Deciphering the insights of poly(ADP-ribosylation) in tumor progression. Med. Res. Rev. 2015, 35, 678–697. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  44. Rodríguez, M.I.; Peralta-Leal, A.; O’Valle, F.; Rodriguez-Vargas, J.M.; Gonzalez-Flores, A.; Majuelos-Melguizo, J.; López, L.; Serrano, S.; de Herreros, A.G.; Rodríguez-Manzaneque, J.C.; et al. PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS Genet. 2013, 9, e1003531. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  45. McPhee, T.R.; McDonald, P.C.; Oloumi, A.; Dedhar, S. Integrin-linked kinase regulates E-cadherin expression through PARP-1. Dev. Dyn. 2008, 237, 2737–2747. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  46. Rodríguez, M.I.; González-Flores, A.; Dantzer, F.; Collard, J.; de Herreros, A.G.; Oliver, F.J. Poly(ADP-ribose)-dependent regulation of Snail1 protein stability. Oncogene 2011, 30, 4365–4372. [Google Scholar] [CrossRef] [Scilit]
  47. Lönn, P.; van der Heide, L.P.; Dahl, M.; Hellman, U.; Heldin, C.H.; Moustakas, A. PARP-1 attenuates Smad-mediated transcription. Mol. Cell 2010, 40, 521–532. [Google Scholar] [CrossRef] [Scilit]
  48. Dahl, M.; Maturi, V.; Lönn, P.; Papoutsoglou, P.; Zieba, A.; Vanlandewijck, M.; van der Heide, L.P.; Watanabe, Y.; Söderberg, O.; Hottiger, M.O.; et al. Fine-tuning of Smad protein function by poly(ADP-ribose) polymerases and poly(ADP-ribose) glycohydrolase during transforming growth factor β signaling. PLoS ONE 2014, 9, e103651. [Google Scholar] [CrossRef] [Scilit]
  49. Lambert, A.W.; Pattabiraman, D.R.; Weinberg, R.A. Emerging Biol.ogical Principles of Metastasis. Cell 2017, 168, 670–691. [Google Scholar] [CrossRef] [Scilit]
  50. Polyak, K.; Weinberg, R.A. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9, 265–273. [Google Scholar] [CrossRef] [Scilit]
  51. Nieto, M.A. Epithelial plasticity: A common theme in embryonic and cancer cells. Science 2013, 342, 1234850. [Google Scholar] [CrossRef] [Scilit]
  52. Overholtzer, M.; Zhang, J.; Smolen, G.A.; Muir, B.; Li, W.; Sgroi, D.C.; Deng, C.X.; Brugge, J.S.; Haber, D.A. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc. Natl. Acad. Sci. USA 2006, 103, 12405–12410. [Google Scholar] [CrossRef] [Scilit]
  53. Lamar, J.M.; Stern, P.; Liu, H.; Schindler, J.W.; Jiang, Z.G.; Hynes, R.O. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc. Natl. Acad. Sci. USA 2012, 109, E2441–E2450. [Google Scholar] [CrossRef] [Scilit]
  54. Zhao, B.; Wei, X.; Li, W.; Udan, R.S.; Yang, Q.; Kim, J.; Xie, J.; Ikenoue, T.; Yu, J.; Li, L.; et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007, 21, 2747–2761. [Google Scholar] [CrossRef] [Scilit]
  55. Zhao, B.; Li, L.; Lu, Q.; Wang, L.H.; Liu, C.Y.; Lei, Q.; Guan, K.L. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev. 2011, 25, 51–63. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  56. Wang, W.; Li, N.; Li, X.; Tran, M.K.; Han, X.; Chen, J. Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins. Cell Rep. 2015, 13, 524–532. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  57. Wu, X.; Chen, H.; Parker, B.; Rubin, E.; Zhu, T.; Lee, J.S.; Argani, P.; Sukumar, S. HOXB7, a homeodomain protein, is overexpressed in breast cancer and confers epithelial-mesenchymal transition. Cancer Res. 2006, 66, 9527–9534. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  58. Wu, X.; Ellmann, S.; Rubin, E.; Gil, M.; Jin, K.; Han, L.; Chen, H.; Kwon, E.M.; Guo, J.; Ha, H.C.; et al. ADP ribosylation by PARP-1 suppresses HOXB7 transcriptional activity. PLoS ONE 2012, 7, e40644. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  59. Pu, H.; Horbinski, C.; Hensley, P.J.; Matuszak, E.A.; Atkinson, T.; Kyprianou, N. PARP-1 regulates epithelial-mesenchymal transition (EMT) in prostate tumorigenesis. Carcinogenesis 2014, 35, 2592–2601. [Google Scholar] [CrossRef] [Scilit]
  60. Karicheva, O.; Rodriguez-Vargas, J.M.; Wadier, N.; Martin-Hernandez, K.; Vauchelles, R.; Magroun, N.; Tissier, A.; Schreiber, V.; Dantzer, F. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis. Oncotarget 2016, 7, 64109–64123. [Google Scholar] [CrossRef] [Scilit]
  61. Navas, T.; Kinders, R.J.; Lawrence, S.M.; Ferry-Galow, K.V.; Borgel, S.; Hollingshead, M.G.; Srivastava, A.K.; Alcoser, S.Y.; Makhlouf, H.R.; Chuaqui, R.; et al. Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas. Cancer Res. 2020, 80, 304–318. [Google Scholar] [CrossRef] [Scilit]
  62. Ordonez, L.D.; Hay, T.; McEwen, R.; Polanska, U.M.; Hughes, A.; Delpuech, O.; Cadogan, E.; Powell, S.; Dry, J.; Tornillo, G.; et al. Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours. Oncotarget 2019, 10, 2586–2606. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  63. Shay, G.; Lynch, C.C.; Fingleton, B. Moving targets: Emerging roles for MMPs in cancer progression and metastasis. Matrix Biol. 2015, 44–46, 200–206. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  64. Yan, B.; Jiang, Z.; Cheng, L.; Chen, K.; Zhou, C.; Sun, L.; Qian, W.; Li, J.; Cao, J.; Xu, Q.; et al. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α. Exp. Cell Res. 2018, 371, 63–71. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  65. Matsui, S.; Osada, S.; Tomita, H.; Komori, S.; Mori, R.; Sanada, Y.; Takahashi, T.; Yamaguchi, K.; Yoshida, K. Clinical significance of aggressive hepatectomy for colorectal liver metastasis, evaluated from the HGF/c-Met pathway. Int. J. Oncol. 2010, 37, 289–297. [Google Scholar] [CrossRef] [Scilit]
  66. Mariani, M.; McHugh, M.; Petrillo, M.; Sieber, S.; He, S.; Andreoli, M.; Wu, Z.; Fiedler, P.; Scambia, G.; Shahabi, S.; et al. HGF/c-Met axis drives cancer aggressiveness in the neo-adjuvant setting of ovarian cancer. Oncotarget 2014, 5, 4855–4867. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  67. Wei, W.; Lv, S.; Zhang, C.; Tian, Y. Potential role of HGF-PARP-1 signaling in invasion of ovarian cancer cells. Int. J. Clin. Exp. Pathol. 2018, 11, 3310–3317. [Google Scholar] [PubMed]
  68. Mishra, M.; Kowluru, R.A. Role of PARP-1 as a novel transcriptional regulator of MMP-9 in diabetic retinopathy. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 1761–1769. [Google Scholar] [CrossRef] [Scilit]
  69. Virág, L. Poly(ADP-ribosyl)ation in asthma and other lung diseases. Pharmacol. Res. 2005, 52, 83–92. [Google Scholar] [CrossRef] [Scilit]
  70. Ghorai, A.; Sarma, A.; Chowdhury, P.; Ghosh, U. PARP-1 depletion in combination with carbon ion exposure significantly reduces MMPs activity and overall increases TIMPs expression in cultured HeLa cells. Radiat. Oncol. 2016, 11, 126. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  71. El-Hamoly, T.; Hegedűs, C.; Lakatos, P.; Kovács, K.; Bai, P.; El-Ghazaly, M.A.; El-Denshary, E.S.; Szabó, É.; Virág, L. Activation of poly(ADP-ribose) polymerase-1 delays wound healing by regulating keratinocyte migration and production of inflammatory mediators. Mol. Med. 2014, 20, 363–371. [Google Scholar] [CrossRef] [Scilit]
  72. Nicolescu, A.C.; Holt, A.; Kandasamy, A.D.; Pacher, P.; Schulz, R. Inhibition of matrix metalloproteinase-2 by PARP inhibitors. Biochem. Biophys. Res. Commun. 2009, 387, 646–650. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  73. Li, Q.; Li, M.; Wang, Y.L.; Fauzee, N.J.; Yang, Y.; Pan, J.; Yang, L.; Lazar, A. RNA interference of PARG could inhibit the metastatic potency of colon carcinoma cells via PI3-kinase/Akt pathway. Cell. Physiol. Biochem. 2012, 29, 361–372. [Google Scholar] [CrossRef] [Scilit]
  74. Kim, J.; Yum, S.; Kang, C.; Kang, S.-J. Gene-gene interactions in gastrointestinal cancer susceptibility. Oncotarget 2016, 7, 67612–67625. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  75. Kim, J.; Pyun, J.A.; Cho, S.W.; Lee, K.; Kwack, K. Lymph node metastasis of gastric cancer is associated with the interaction between poly (ADP-ribose) polymerase 1 and matrix metallopeptidase 2. DNA Cell Biol. 2011, 30, 1011–1017. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  76. Schlesinger, M. Role of platelets and platelet receptors in cancer metastasis. J. Hematol. Oncol. 2018, 11, 125. [Google Scholar] [CrossRef] [Scilit]
  77. Placke, T.; Kopp, H.G.; Salih, H.R. The wolf in sheep’s clothing: Platelet-derived "pseudo self" impairs cancer cell "missing self" recognition by NK cells. Oncoimmunology 2012, 1, 557–559. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  78. Zingarelli, B.; Salzman, A.L.; Szabó, C. Genetic disruption of poly (ADP-ribose) synthetase inhibits the expression of P-selectin and intercellular adhesion molecule-1 in myocardial ischemia/reperfusion injury. Circ. Res. 1998, 83, 85–94. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  79. Yan, J.; Li, M.; Threadgill, M.D.; Wang, Y.; Fu, W. Decreasing P-selectin and ICAM-1 via activating Akt: A possible mechanism by which PARG inhibits adhesion of mouse colorectal carcinoma CT26 cells to platelets. Cancer Gene Ther. 2013, 20, 487–492. [Google Scholar] [CrossRef] [Scilit]
  80. Dutta, P.; Paico, K.; Gomez, G.; Wu, Y.; Vadgama, J.V. Transcriptional Regulation of CCL2 by PARP1 Is a Driver for Invasiveness in Breast Cancer. Cancers (Basel) 2020, 12, 1317. [Google Scholar] [CrossRef] [Scilit]
  81. Xu, F.; Sun, Y.; Yang, S.Z.; Zhou, T.; Jhala, N.; McDonald, J.; Chen, Y. Cytoplasmic PARP-1 promotes pancreatic cancer tumorigenesis and resistance. Int. J. Cancer 2019, 145, 474–483. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  82. Zhang, X.H.; Wang, Q.; Gerald, W.; Hudis, C.A.; Norton, L.; Smid, M.; Foekens, J.A.; Massagué, J. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 2009, 16, 67–78. [Google Scholar] [CrossRef] [Scilit]
  83. Marković, J.; Grdović, N.; Dinić, S.; Karan-Djurašević, T.; Uskoković, A.; Arambašić, J.; Mihailović, M.; Pavlović, S.; Poznanović, G.; Vidaković, M. PARP-1 and YY1 are important novel regulators of CXCL12 gene transcription in rat pancreatic beta cells. PLoS ONE 2013, 8, e59679. [Google Scholar] [CrossRef] [Scilit]
  84. Hsu, E.C.; Rice, M.A.; Bermudez, A.; Marques, F.J.G.; Aslan, M.; Liu, S.; Ghoochani, A.; Zhang, C.A.; Chen, Y.S.; Zlitni, A.; et al. Trop2 is a driver of metastatic prostate cancer with neuroendocrine phenotype via PARP1. Proc. Natl. Acad. Sci. USA 2020, 117, 2032–2042. [Google Scholar] [CrossRef] [Scilit]
  85. Zuo, H.; Yang, D.; Yang, Q.; Tang, H.; Fu, Y.X.; Wan, Y. Differential regulation of breast cancer bone metastasis by PARP1 and PARP2. Nat. Commun. 2020, 11, 1578. [Google Scholar] [CrossRef] [Scilit]
  86. D’Alterio, C.; Scala, S.; Sozzi, G.; Roz, L.; Bertolini, G. Paradoxical effects of chemotherapy on tumor relapse and metastasis promotion. Semin. Cancer Biol. 2020, 60, 351–361. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  87. Dvorak, H.F. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315, 1650–1659. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  88. Schäfer, M.; Werner, S. Cancer as an overhealing wound: An old hypothesis revisited. Nat. Rev. Mol. Cell Biol. 2008, 9, 628–638. [Google Scholar] [CrossRef] [Scilit]
  89. Hegedus, C.; Kovacs, K.; Polgar, Z.; Regdon, Z.; Szabo, E.; Robaszkiewicz, A.; Forman, H.J.; Martner, A.; Virag, L. Redox control of cancer cell destruction. Redox Biol. 2018, 16, 59–74. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  90. Brady, P.N.; Goel, A.; Johnson, M.A. Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity. Microbiol. Mol. Biol. Rev. 2019, 83. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  91. Bai, P.; Virag, L. Role of poly(ADP-ribose) polymerases in the regulation of inflammatory processes. Febs Lett. 2012, 586, 3771–3777. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  92. Goldfarb, R.D.; Marton, A.; Szabo, E.; Virag, L.; Salzman, A.L.; Glock, D.; Akhter, I.; McCarthy, R.; Parrillo, J.E.; Szabo, C. Protective effect of a novel, potent inhibitor of poly(adenosine 5′-diphosphate-ribose) synthetase in a porcine model of severe bacterial sepsis. Crit. Care Med. 2002, 30, 974–980. [Google Scholar] [CrossRef] [Scilit]
  93. Liaudet, L.; Soriano, F.G.; Szabo, E.; Virag, L.; Mabley, J.G.; Salzman, A.L.; Szabo, C. Protection against hemorrhagic shock in mice genetically deficient in poly(ADP-ribose)polymerase. Proc. Natl. Acad. Sci. USA 2000, 97, 10203–10208. [Google Scholar] [CrossRef] [Scilit]
  94. Mabley, J.; Virag, L.; Jagtap, P.; Szabo, E.; Prendergast, R.; Perretti, M.; Getting, S.; Szabo, C. Effect of a novel poly (ADP-ribose) polymerase (PARP) inhibitor in rodent models of local inflammation. Faseb J. 2001, 15, A242. [Google Scholar]
  95. Pacher, P.; Liaudet, L.; Mabley, J.G.; Soriano, F.G.; Virag, L.; Szabo, C. Activation of poly(ADP-ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Faseb J. 2002, 16, A20. [Google Scholar]
  96. Mabley, J.G.; Jagtap, P.; Perretti, M.; Getting, S.J.; Salzman, A.L.; Virag, L.; Szabo, E.; Soriano, F.G.; Liaudet, L.; Abdelkarim, G.E.; et al. Anti-inflammatory effects of a novel, potent inhibitor of poly (ADP-ribose) polymerase. Inflamm. Res. 2001, 50, 561–569. [Google Scholar] [CrossRef] [Scilit]
  97. Marton, A.; Szabo, E.; Virag, L.; Salzman, A.; Glock, D.; McCarthy, R.; Parrillo, J.E.; Sabo, C.; Goldfarb, R.D. Protective effect of a novel inhibitor of poly (ADP-ribose) synthetase in a porcine model of peritonitis. Faseb J. 2001, 15, A1123. [Google Scholar]
  98. Liaudet, L.; Pacher, P.; Mabley, J.G.; Virag, L.; Soriano, F.G.; Hasko, G.; Szabo, C. Activation of poly(ADP-ribose) polymerase-1 is a central mechanism of lipopolysaccharide-induced acute lung inflammation. Am. J. Resp. Crit. Care 2002, 165, 372–377. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  99. Bakondi, E.; Bai, P.; Bak, I.; Szabo, E.; Gergely, P.; Szabo, C.; Virag, L. Role of poly(ADP-ribose) polymerase in contact hypersensitivity. Faseb J. 2002, 16, A674–A675. [Google Scholar]
  100. Virag, L.; Szabo, E. Complex Role of Poly(Adp-Ribosyl)Ation in Shock and Other Oxidative Stress-Related Pathologies. Shock 2011, 36, 34. [Google Scholar]
  101. Virag, L.; Bai, P.; Bak, I.; Pacher, P.; Mabley, J.; Liaudet, L.; Bakondl, E.; Gergely, P.; Kollai, M.; Szabo, C. Effects of poly(ADP-ribose) polymerase inhibition on inflammatory cell migration in a murine model of asthma. Med. Sci. Monitor 2004, 10, Br77–Br83. [Google Scholar]
  102. Soriano, F.G.; Liaudet, L.; Szabo, E.; Virag, L.; Mabley, J.G.; Pacher, P.; Szabo, C. Resistance to acute septic peritonitis in poly(ADP-ribose) polymerase-1 deficient mice. Faseb J. 2002, 16, A1120. [Google Scholar] [CrossRef] [Scilit]
  103. Scott, G.S.; Hake, P.; Kean, R.B.; Virag, L.; Szabo, C.; Hooper, D.C. Role of poly(ADP-ribose) synthetase activation in the development of experimental allergic encephalomyelitis. J. Neuroimmunol. 2001, 117, 78–86. [Google Scholar] [CrossRef] [Scilit]
  104. Szabo, E.; Bodnar, E.; Erdelyi, K.; Hegedus, C.; Bakondi, E.; Remenyik, E.; Virag, L. Possible role of the nitric oxide-peroxynitrite-poly(ADP-ribose) polymerase pathway in chronic wounds. J. Investig. Dermatol. 2009, 129, S96. [Google Scholar]
  105. El-Hamoly, T.; Hajnady, Z.; Nagy-Penzes, M.; Bakondi, E.; Regdon, Z.; Demeny, M.A.; Kovacs, K.; Hegedus, C.; Abd El-Rahman, S.S.; Szabo, E.; et al. Poly(ADP-Ribose) Polymerase 1 Promotes Inflammation and Fibrosis in a Mouse Model of Chronic Pancreatitis. Int. J. Mol. Sci. 2021, 22, 3593. [Google Scholar] [CrossRef] [Scilit]
  106. Hassa, P.O.; Hottiger, M.O. The functional role of poly(ADP-ribose)polymerase 1 as novel coactivator of NF-kappaB in inflammatory disorders. Cell. Mol. Life Sci. 2002, 59, 1534–1553. [Google Scholar] [CrossRef] [Scilit]
  107. Oliver, F.J.; Ménissier-de Murcia, J.; Nacci, C.; Decker, P.; Andriantsitohaina, R.; Muller, S.; de la Rubia, G.; Stoclet, J.C.; de Murcia, G. Resistance to endotoxic shock as a consequence of defective NF-kappaB activation in poly (ADP-ribose) polymerase-1 deficient mice. Embo J. 1999, 18, 4446–4454. [Google Scholar] [CrossRef] [Scilit]
  108. Oei, S.L.; Shi, Y. Poly(ADP-ribosyl)ation of transcription factor Yin Yang 1 under conditions of DNA damage. Biochem. Biophys. Res. Commun. 2001, 285, 27–31. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  109. Laugesen, A.; Hojfeldt, J.W.; Helin, K. Role of the Polycomb Repressive Complex 2 (PRC2) in Transcriptional Regulation and Cancer. Cold Spring Harb. Perspect. Med. 2016, 6. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  110. Yang, A.Y.; Choi, E.B.; So Park, M.; Kim, S.K.; Park, M.S.; Kim, M.Y. PARP1 and PRC2 double deficiency promotes BRCA-proficient breast cancer growth by modification of the tumor microenvironment. Febs J. 2020. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  111. Iwata, H.; Goettsch, C.; Sharma, A.; Ricchiuto, P.; Goh, W.W.; Halu, A.; Yamada, I.; Yoshida, H.; Hara, T.; Wei, M.; et al. PARP9 and PARP14 cross-regulate macrophage activation via STAT1 ADP-ribosylation. Nat. Commun. 2016, 7, 12849. [Google Scholar] [CrossRef] [Scilit]
  112. Locati, M.; Curtale, G.; Mantovani, A. Diversity, Mechanisms, and Significance of Macrophage Plasticity. Annu. Rev. Pathol. 2020, 15, 123–147. [Google Scholar] [CrossRef] [Scilit]
  113. Levaot, N.; Voytyuk, O.; Dimitriou, I.; Sircoulomb, F.; Chandrakumar, A.; Deckert, M.; Krzyzanowski, P.M.; Scotter, A.; Gu, S.; Janmohamed, S.; et al. Loss of Tankyrase-mediated destruction of 3BP2 is the underlying pathogenic mechanism of cherubism. Cell 2011, 147, 1324–1339. [Google Scholar] [CrossRef] [Scilit]
  114. Verheugd, P.; Forst, A.H.; Milke, L.; Herzog, N.; Feijs, K.L.; Kremmer, E.; Kleine, H.; Luscher, B. Regulation of NF-kappaB signalling by the mono-ADP-ribosyltransferase ARTD10. Nat. Commun. 2013, 4, 1683. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  115. Ali, S.O.; Khan, F.A.; Galindo-Campos, M.A.; Yelamos, J. Understanding specific functions of PARP-2: New lessons for cancer therapy. Am. J. Cancer Res. 2016, 6, 1842–1863. [Google Scholar] [PubMed]
  116. Popoff, I.; Jijon, H.; Monia, B.; Tavernini, M.; Ma, M.; McKay, R.; Madsen, K. Antisense oligonucleotides to poly(ADP-ribose) polymerase-2 ameliorate colitis in interleukin-10-deficient mice. J. Pharmacol. Exp. Ther. 2002, 303, 1145–1154. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  117. Kamboj, A.; Lu, P.; Cossoy, M.B.; Stobart, J.L.; Dolhun, B.A.; Kauppinen, T.M.; de Murcia, G.; Anderson, C.M. Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis. J. Neuroinflamm. 2013, 10, 49. [Google Scholar] [CrossRef] [Scilit]
  118. Kickhoefer, V.A.; Siva, A.C.; Kedersha, N.L.; Inman, E.M.; Ruland, C.; Streuli, M.; Rome, L.H. The 193-kD vault protein, VPARP, is a novel poly(ADP-ribose) polymerase. J. Cell Biol. 1999, 146, 917–928. [Google Scholar] [CrossRef] [Scilit]
  119. Peng, N.; Liu, S.; Xia, Z.; Ren, S.; Feng, J.; Jing, M.; Gao, X.; Wiemer, E.A.; Zhu, Y. Inducible Major Vault Protein Plays a Pivotal Role in Double-Stranded RNA- or Virus-Induced Proinflammatory Response. J. Immunol. 2016, 196, 2753–2766. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  120. Ben, J.; Zhang, Y.; Zhou, R.; Zhang, H.; Zhu, X.; Li, X.; Zhang, H.; Li, N.; Zhou, X.; Bai, H.; et al. Major vault protein regulates class A scavenger receptor-mediated tumor necrosis factor-α synthesis and apoptosis in macrophages. J. Biol. Chem. 2013, 288, 20076–20084. [Google Scholar] [CrossRef] [Scilit]
  121. Ben, J.; Jiang, B.; Wang, D.; Liu, Q.; Zhang, Y.; Qi, Y.; Tong, X.; Chen, L.; Liu, X.; Zhang, Y.; et al. Major vault protein suppresses obesity and atherosclerosis through inhibiting IKK-NF-κB signaling mediated inflammation. Nat. Commun. 2019, 10, 1801. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  122. Bindesbøll, C.; Tan, S.; Bott, D.; Cho, T.; Tamblyn, L.; MacPherson, L.; Grønning-Wang, L.; Nebb, H.I.; Matthews, J. TCDD-inducible poly-ADP-ribose polymerase (TIPARP/PARP7) mono-ADP-ribosylates and co-activates liver X receptors. Biochem. J. 2016, 473, 899–910. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  123. Fowler, A.J.; Sheu, M.Y.; Schmuth, M.; Kao, J.; Fluhr, J.W.; Rhein, L.; Collins, J.L.; Willson, T.M.; Mangelsdorf, D.J.; Elias, P.M.; et al. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: Liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J. Investig. Dermatol. 2003, 120, 246–255. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  124. Welsby, I.; Hutin, D.; Gueydan, C.; Kruys, V.; Rongvaux, A.; Leo, O. PARP12, an interferon-stimulated gene involved in the control of protein translation and inflammation. J. Biol. Chem. 2014, 289, 26642–26657. [Google Scholar] [CrossRef] [Scilit]
  125. Salminen, A.; Kauppinen, A.; Kaarniranta, K. Emerging role of NF-kappaB signaling in the induction of senescence-associated secretory phenotype (SASP). Cell Signal 2012, 24, 835–845. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  126. Ohanna, M.; Giuliano, S.; Bonet, C.; Imbert, V.; Hofman, V.; Zangari, J.; Bille, K.; Robert, C.; Bressac-de Paillerets, B.; Hofman, P.; et al. Senescent cells develop a PARP-1 and nuclear factor-{kappa}B-associated secretome (PNAS). Genes Dev. 2011, 25, 1245–1261. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  127. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: Integrating immunity’s roles in cancer suppression and promotion. Science 2011, 331, 1565–1570. [Google Scholar] [CrossRef] [Scilit]
  128. Svane, I.M.; Engel, A.M.; Nielsen, M.B.; Ljunggren, H.G.; Rygaard, J.; Werdelin, O. Chemically induced sarcomas from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur. J. Immunol. 1996, 26, 1844–1850. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  129. Yang, L.; Pang, Y.; Moses, H.L. TGF-beta and immune cells: An important regulatory axis in the tumor microenvironment and progression. Trends Immunol. 2010, 31, 220–227. [Google Scholar] [CrossRef] [Scilit]
  130. Shields, J.D.; Kourtis, I.C.; Tomei, A.A.; Roberts, J.M.; Swartz, M.A. Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 2010, 328, 749–752. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  131. Arrieta, V.A.; Cacho-Díaz, B.; Zhao, J.; Rabadan, R.; Chen, L.; Sonabend, A.M. The possibility of cancer immune editing in gliomas. A critical review. Oncoimmunology 2018, 7, e1445458. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  132. Waldhauer, I.; Steinle, A. NK cells and cancer immunosurveillance. Oncogene 2008, 27, 5932–5943. [Google Scholar] [CrossRef] [Scilit]
  133. Sharma, P.; Allison, J.P. Immune checkpoint targeting in cancer therapy: Toward combination strategies with curative potential. Cell 2015, 161, 205–214. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  134. Chamoto, K.; Hatae, R.; Honjo, T. Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int. J. Clin. Oncol. 2020, 25, 790–800. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  135. Nasta, F.; Laudisi, F.; Sambucci, M.; Rosado, M.M.; Pioli, C. Increased Foxp3+ regulatory T cells in poly(ADP-Ribose) polymerase-1 deficiency. J. Immunol. 2010, 184, 3470–3477. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  136. Galindo-Campos, M.A.; Bedora-Faure, M.; Farres, J.; Lescale, C.; Moreno-Lama, L.; Martinez, C.; Martin-Caballero, J.; Ampurdanes, C.; Aparicio, P.; Dantzer, F.; et al. Coordinated signals from the DNA repair enzymes PARP-1 and PARP-2 promotes B-cell development and function. Cell Death Differ. 2019, 26, 2667–2681. [Google Scholar] [CrossRef] [Scilit]
  137. Navarro, J.; Gozalbo-Lopez, B.; Mendez, A.C.; Dantzer, F.; Schreiber, V.; Martinez, C.; Arana, D.M.; Farres, J.; Revilla-Nuin, B.; Bueno, M.F.; et al. PARP-1/PARP-2 double deficiency in mouse T cells results in faulty immune responses and T lymphomas. Sci. Rep. 2017, 7, 41962. [Google Scholar] [CrossRef] [Scilit]
  138. Szabó, É.; Kovács, I.; Grune, T.; Haczku, A.; Virág, L. PARP-1: A new player in the asthma field? Allergy 2011, 66, 811–814. [Google Scholar] [CrossRef] [Scilit]
  139. Ghonim, M.A.; Pyakurel, K.; Ibba, S.V.; Al-Khami, A.A.; Wang, J.; Rodriguez, P.; Rady, H.F.; El-Bahrawy, A.H.; Lammi, M.R.; Mansy, M.S.; et al. PARP inhibition by olaparib or gene knockout blocks asthma-like manifestation in mice by modulating CD4(+) T cell function. J. Transl. Med. 2015, 13, 225. [Google Scholar] [CrossRef] [Scilit]
  140. Scott, G.S.; Kean, R.B.; Mikheeva, T.; Fabis, M.J.; Mabley, J.G.; Szabó, C.; Hooper, D.C. The therapeutic effects of PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide.HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. J. Pharmacol. Exp. Ther. 2004, 310, 1053–1061. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  141. Chiarugi, A. Inhibitors of poly(ADP-ribose) polymerase-1 suppress transcriptional activation in lymphocytes and ameliorate autoimmune encephalomyelitis in rats. Br. J. Pharmacol. 2002, 137, 761–770. [Google Scholar] [CrossRef] [Scilit]
  142. Valdor, R.; Schreiber, V.; Saenz, L.; Martínez, T.; Muñoz-Suano, A.; Dominguez-Villar, M.; Ramírez, P.; Parrilla, P.; Aguado, E.; García-Cózar, F.; et al. Regulation of NFAT by poly(ADP-ribose) polymerase activity in T cells. Mol. Immunol. 2008, 45, 1863–1871. [Google Scholar] [CrossRef] [Scilit]
  143. Zhang, P.; Maruyama, T.; Konkel, J.E.; Abbatiello, B.; Zamarron, B.; Wang, Z.Q.; Chen, W. PARP-1 controls immunosuppressive function of regulatory T cells by destabilizing Foxp3. PLoS ONE 2013, 8, e71590. [Google Scholar] [CrossRef] [Scilit]
  144. Luo, X.; Nie, J.; Wang, S.; Chen, Z.; Chen, W.; Li, D.; Hu, H.; Li, B. Poly(ADP-ribosyl)ation of FOXP3 protein mediated by PARP-1 regulates the function of regulatory T cells. J. Biol. Chem. 2016, 291, 1201. [Google Scholar] [CrossRef] [Scilit]
  145. Kunze, F.A.; Bauer, M.; Komuczki, J.; Lanzinger, M.; Gunasekera, K.; Hopp, A.K.; Lehmann, M.; Becher, B.; Müller, A.; Hottiger, M.O. ARTD1 in Myeloid Cells Controls the IL-12/18-IFN-γ Axis in a Model of Sterile Sepsis, Chronic Bacterial Infection, and Cancer. J. Immunol. 2019, 202, 1406–1416. [Google Scholar] [CrossRef] [Scilit]
  146. Shou, Q.; Fu, H.; Huang, X.; Yang, Y. PARP-1 controls NK cell recruitment to the site of viral infection. JCI Insight 2019, 4. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  147. Echeverri Tirado, L.C.; Ghonim, M.A.; Wang, J.; Al-Khami, A.A.; Wyczechowska, D.; Luu, H.H.; Kim, H.; Sanchez-Pino, M.D.; Yélamos, J.; Yassin, L.M.; et al. PARP-1 Is Critical for Recruitment of Dendritic Cells to the Lung in a Mouse Model of Asthma but Dispensable for Their Differentiation and Function. Mediators Inflamm. 2019, 2019, 1656484. [Google Scholar] [CrossRef] [Scilit]
  148. Cavone, L.; Aldinucci, A.; Ballerini, C.; Biagioli, T.; Moroni, F.; Chiarugi, A. PARP-1 inhibition prevents CNS migration of dendritic cells during EAE, suppressing the encephalitogenic response and relapse severity. Mult. Scler. 2011, 17, 794–807. [Google Scholar] [CrossRef] [Scilit]
  149. Moreno-Lama, L.; Galindo-Campos, M.A.; Martínez, C.; Comerma, L.; Vazquez, I.; Vernet-Tomas, M.; Ampurdanés, C.; Lutfi, N.; Martin-Caballero, J.; Dantzer, F.; et al. Coordinated signals from PARP-1 and PARP-2 are required to establish a proper T cell immune response to breast tumors in mice. Oncogene 2020, 39, 2835–2843. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  150. Chacon-Cabrera, A.; Fermoselle, C.; Salmela, I.; Yelamos, J.; Barreiro, E. MicroRNA expression and protein acetylation pattern in respiratory and limb muscles of Parp-1(-/-) and Parp-2(-/-) mice with lung cancer cachexia. Biochim. Biophys. Acta 2015, 1850, 2530–2543. [Google Scholar] [CrossRef] [Scilit] [PubMed]
  151. Jiao, S.; Xia, W.; Yamaguchi, H.; Wei, Y.; Chen, M.K.; Hsu, J.M.; Hsu, J.L.; Yu, W.H.; Du, Y.; Lee, H.H.; et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin. Cancer Res. 2017, 23, 3711–3720. [Google Scholar] [CrossRef] [Scilit]
  152. Navas, L.E.; Carnero, A. NAD(+) metabolism, stemness, the immune response, and cancer. Signal Transduct. Target Ther. 2021, 6, 2. [Google Scholar] [CrossRef] [Scilit]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.